Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome

R. Laczik, P. Szodoray, K. Veres, E. Szomják, I. Csípő, S. Sipka, Y. Shoenfeld, Z. Szekanecz, P. Soltész

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Objectives. Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS). Methods. In total 54 patients with ACS and 41 matched healthy controls were involved in this prospective study. Serum IgG anti-oxLDL levels were assessed by ELISA. Results. Higher IgG anti-oxLDL levels were found in patients with ACS versus controls (22.8 ± 23.3 vs. 7.5 ± 5.27 EU/ml, p <0.0001). IgG anti-oxLDL concentrations were significantly higher in ACS patients with unstable clinical complications (circulatory insufficiency, malignant arrhythmias, recurring ischaemic pain, positive stress-test, need for urgent coronary intervention or sudden cardiac death) versus those without such complications (30.0 vs. 11.7 EU/ml, p <0.001). Twelve patients (22%) were taking statins. Patients on statins had a significant reduction in clinical complications (33%) versus patients not receiving statin therapy (61%). IgG anti-oxLDL levels were also different in these two groups (11.4 vs. 25.8 EU/ml, respectively; p = 0.03). Serum IgG anti-oxLDL levels correlated with the subsequent development of unstable coronary events. Levels of anti-oxLDL significantly decreased in response to statin therapy, independently of its lipid-lowering effect. Conclusions. Anti-oxLDL antibodies are involved in ACS. The association of anti-oxLDL with unstable clinical complications may indicate the role of this antibody in plaque destabilization.

Original languageEnglish
Pages (from-to)730-735
Number of pages6
JournalLupus
Volume20
Issue number7
DOIs
Publication statusPublished - Jun 2011

Fingerprint

Acute Coronary Syndrome
Immunoglobulin G
Antibodies
Hydroxymethylglutaryl-CoA Reductase Inhibitors
oxidized low density lipoprotein
low density lipoprotein inhibitor
Sudden Cardiac Death
Atherosclerotic Plaques
Serum
Exercise Test
Cardiac Arrhythmias
Anti-Idiotypic Antibodies
Enzyme-Linked Immunosorbent Assay
Prospective Studies
Lipids
Pain

Keywords

  • acute coronary syndrome
  • anti-oxidized LDL antibody
  • atherosclerosis
  • statin therapy

ASJC Scopus subject areas

  • Rheumatology

Cite this

Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome. / Laczik, R.; Szodoray, P.; Veres, K.; Szomják, E.; Csípő, I.; Sipka, S.; Shoenfeld, Y.; Szekanecz, Z.; Soltész, P.

In: Lupus, Vol. 20, No. 7, 06.2011, p. 730-735.

Research output: Contribution to journalArticle

@article{7558ab71ba47415e9aa68a66a72ff57d,
title = "Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome",
abstract = "Objectives. Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS). Methods. In total 54 patients with ACS and 41 matched healthy controls were involved in this prospective study. Serum IgG anti-oxLDL levels were assessed by ELISA. Results. Higher IgG anti-oxLDL levels were found in patients with ACS versus controls (22.8 ± 23.3 vs. 7.5 ± 5.27 EU/ml, p <0.0001). IgG anti-oxLDL concentrations were significantly higher in ACS patients with unstable clinical complications (circulatory insufficiency, malignant arrhythmias, recurring ischaemic pain, positive stress-test, need for urgent coronary intervention or sudden cardiac death) versus those without such complications (30.0 vs. 11.7 EU/ml, p <0.001). Twelve patients (22{\%}) were taking statins. Patients on statins had a significant reduction in clinical complications (33{\%}) versus patients not receiving statin therapy (61{\%}). IgG anti-oxLDL levels were also different in these two groups (11.4 vs. 25.8 EU/ml, respectively; p = 0.03). Serum IgG anti-oxLDL levels correlated with the subsequent development of unstable coronary events. Levels of anti-oxLDL significantly decreased in response to statin therapy, independently of its lipid-lowering effect. Conclusions. Anti-oxLDL antibodies are involved in ACS. The association of anti-oxLDL with unstable clinical complications may indicate the role of this antibody in plaque destabilization.",
keywords = "acute coronary syndrome, anti-oxidized LDL antibody, atherosclerosis, statin therapy",
author = "R. Laczik and P. Szodoray and K. Veres and E. Szomj{\'a}k and I. Cs{\'i}pő and S. Sipka and Y. Shoenfeld and Z. Szekanecz and P. Solt{\'e}sz",
year = "2011",
month = "6",
doi = "10.1177/0961203311398884",
language = "English",
volume = "20",
pages = "730--735",
journal = "Lupus",
issn = "0961-2033",
publisher = "SAGE Publications Ltd",
number = "7",

}

TY - JOUR

T1 - Assessment of IgG antibodies to oxidized LDL in patients with acute coronary syndrome

AU - Laczik, R.

AU - Szodoray, P.

AU - Veres, K.

AU - Szomják, E.

AU - Csípő, I.

AU - Sipka, S.

AU - Shoenfeld, Y.

AU - Szekanecz, Z.

AU - Soltész, P.

PY - 2011/6

Y1 - 2011/6

N2 - Objectives. Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS). Methods. In total 54 patients with ACS and 41 matched healthy controls were involved in this prospective study. Serum IgG anti-oxLDL levels were assessed by ELISA. Results. Higher IgG anti-oxLDL levels were found in patients with ACS versus controls (22.8 ± 23.3 vs. 7.5 ± 5.27 EU/ml, p <0.0001). IgG anti-oxLDL concentrations were significantly higher in ACS patients with unstable clinical complications (circulatory insufficiency, malignant arrhythmias, recurring ischaemic pain, positive stress-test, need for urgent coronary intervention or sudden cardiac death) versus those without such complications (30.0 vs. 11.7 EU/ml, p <0.001). Twelve patients (22%) were taking statins. Patients on statins had a significant reduction in clinical complications (33%) versus patients not receiving statin therapy (61%). IgG anti-oxLDL levels were also different in these two groups (11.4 vs. 25.8 EU/ml, respectively; p = 0.03). Serum IgG anti-oxLDL levels correlated with the subsequent development of unstable coronary events. Levels of anti-oxLDL significantly decreased in response to statin therapy, independently of its lipid-lowering effect. Conclusions. Anti-oxLDL antibodies are involved in ACS. The association of anti-oxLDL with unstable clinical complications may indicate the role of this antibody in plaque destabilization.

AB - Objectives. Circulating IgG antibodies to oxidized low-density lipoprotein (anti-oxLDL) have been implicated in the development of atherosclerotic plaques. In this study, we investigated the prognostic value of IgG anti-oxLDL antibodies in patients with acute coronary syndrome (ACS). Methods. In total 54 patients with ACS and 41 matched healthy controls were involved in this prospective study. Serum IgG anti-oxLDL levels were assessed by ELISA. Results. Higher IgG anti-oxLDL levels were found in patients with ACS versus controls (22.8 ± 23.3 vs. 7.5 ± 5.27 EU/ml, p <0.0001). IgG anti-oxLDL concentrations were significantly higher in ACS patients with unstable clinical complications (circulatory insufficiency, malignant arrhythmias, recurring ischaemic pain, positive stress-test, need for urgent coronary intervention or sudden cardiac death) versus those without such complications (30.0 vs. 11.7 EU/ml, p <0.001). Twelve patients (22%) were taking statins. Patients on statins had a significant reduction in clinical complications (33%) versus patients not receiving statin therapy (61%). IgG anti-oxLDL levels were also different in these two groups (11.4 vs. 25.8 EU/ml, respectively; p = 0.03). Serum IgG anti-oxLDL levels correlated with the subsequent development of unstable coronary events. Levels of anti-oxLDL significantly decreased in response to statin therapy, independently of its lipid-lowering effect. Conclusions. Anti-oxLDL antibodies are involved in ACS. The association of anti-oxLDL with unstable clinical complications may indicate the role of this antibody in plaque destabilization.

KW - acute coronary syndrome

KW - anti-oxidized LDL antibody

KW - atherosclerosis

KW - statin therapy

UR - http://www.scopus.com/inward/record.url?scp=79957604404&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957604404&partnerID=8YFLogxK

U2 - 10.1177/0961203311398884

DO - 10.1177/0961203311398884

M3 - Article

C2 - 21505011

AN - SCOPUS:79957604404

VL - 20

SP - 730

EP - 735

JO - Lupus

JF - Lupus

SN - 0961-2033

IS - 7

ER -